List of Excipients in Branded Drug ARTICAINE HYDROCHLORIDE AND EPINEPHRINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Henry Schein	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE	articaine hydrochloride and epinephrine	0404-6620	SODIUM CHLORIDE
Henry Schein	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE	articaine hydrochloride and epinephrine	0404-6620	SODIUM HYDROXIDE
Henry Schein	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE	articaine hydrochloride and epinephrine	0404-6620	SODIUM METABISULFITE
Henry Schein	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE	articaine hydrochloride and epinephrine	0404-6620	WATER
Burkhart Dental Supply Co Inc	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE	articaine hydrochloride, epinephrine bitartrate	43498-816	SODIUM CHLORIDE

Articaine Hydrochloride and Epinephrine Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Articaine hydrochloride and epinephrine is a mature dental local-anesthetic combination with limited conventional patent protection and meaningful formulation opportunities. The strongest commercial positions are likely to come from preservative-free packaging, improved cartridge stability, differentiated epinephrine concentrations, lower-waste delivery systems, global regulatory execution, and manufacturing reliability rather than from new chemical-entity patents.

The reference U.S. product is Septocaine, a sterile injectable solution containing articaine hydrochloride 40 mg/mL with epinephrine 1:100,000 or 1:200,000. Key formulation components include sodium chloride, sodium metabisulfite and water for injection. The product is supplied in single-use dental cartridges and is administered by infiltration or nerve block during dental procedures (FDA, 2023a).

What is the formulation profile of articaine hydrochloride and epinephrine?

Articaine hydrochloride is an amide local anesthetic used for dental anesthesia. Epinephrine provides local vasoconstriction, slowing systemic absorption and extending the duration of anesthesia. The commercial formulation is an acidic, sterile aqueous solution packaged in dental cartridges.

Component	Typical function
Articaine hydrochloride	Local anesthetic active ingredient
Epinephrine	Vasoconstrictor and duration-enhancing agent
Sodium chloride	Tonicity adjustment
Sodium metabisulfite	Antioxidant protecting epinephrine
Water for injection	Sterile vehicle
pH adjustment system	Maintains formulation stability and tolerability

The reference products use articaine at 40 mg/mL. Epinephrine is supplied at either 1:100,000 or 1:200,000. The 1:100,000 presentation generally supports stronger vasoconstriction, while the 1:200,000 presentation reduces epinephrine exposure and may be selected when a lower vasoconstrictor load is preferred.

The central formulation constraint is epinephrine oxidation. Epinephrine is sensitive to oxygen, light, elevated temperature and alkaline conditions. Sodium metabisulfite protects the vasoconstrictor but creates labeling and market-access considerations for patients with sulfite sensitivity.

What excipients protect articaine and epinephrine stability?

Sodium metabisulfite is the principal functional excipient in the U.S. reference formulation. Its role is to reduce oxidative degradation of epinephrine during storage. Removing or reducing sulfite would require a different stability strategy and would likely create a substantial regulatory burden.

Sodium metabisulfite

Sodium metabisulfite provides antioxidant protection but has several commercial disadvantages:

• It requires a sulfite warning in labeling.
• It can be unacceptable to selected patients and dental practitioners.
• Its effectiveness depends on concentration, oxygen exposure and container closure.
• Excessive levels can affect pH and tolerability.
• It does not eliminate the need for light and temperature control.

A sulfite-free product could have commercial appeal, but the technical route is difficult. Possible approaches include lower oxygen headspace, improved cartridge glass, tighter elastomer closures, oxygen-scavenging secondary packaging, nitrogen processing and alternative antioxidants. Each approach would require extensive compatibility, extractables, leachables and long-term stability testing.

Sodium chloride

Sodium chloride is used primarily to adjust tonicity. Its concentration must be balanced against pH, osmolality, injection comfort and compatibility with the active ingredients. It is unlikely to provide meaningful differentiation by itself.

Water for injection

Water quality is critical because articaine hydrochloride and epinephrine are administered parenterally. Control of bioburden, endotoxin, particulate matter and dissolved oxygen is central to manufacturing performance.

pH control

The formulation must preserve epinephrine stability without producing excessive injection discomfort. More acidic solutions generally improve epinephrine stability but may increase tissue irritation. A higher pH may improve comfort but can accelerate oxidation and alter chemical stability.

A commercial development program should optimize pH as a multidimensional variable, measuring:

• Epinephrine assay and related substances
• Articaine assay and degradation products
• Color change
• pH drift
• Osmolality
• Particulates
• Container closure integrity
• In-use stability after cartridge exposure

What formulations are protected by patents?

The principal commercial opportunity is generic and differentiated formulation development, not reliance on a dominant active-ingredient patent.

Articaine hydrochloride has been marketed for decades, and the principal composition and use patents associated with the drug are generally expired in major markets. U.S. Orange Book status should be checked for each relevant NDA and supplement before launch because listed patents can vary by product, dosage form and indication. Public FDA materials identify Septocaine as an approved dental injection containing articaine hydrochloride and epinephrine (FDA, 2023a; FDA, 2024).

Potentially protectable developments include:

1. A specific sulfite-free formulation.
2. A defined antioxidant combination.
3. A low-oxygen cartridge filling process.
4. A cartridge closure with improved oxygen barrier performance.
5. A formulation with a defined pH and osmolality range.
6. A dual-strength epinephrine product family.
7. A ready-to-use cartridge with improved light protection.
8. A lower-volume or high-concentration presentation.
9. A formulation designed for automated dental injectors.
10. A manufacturing process that reduces epinephrine degradation.

A formulation patent must claim a genuine technical relationship between composition and performance. Broad claims covering articaine, epinephrine, sodium chloride, sulfite and water are likely to face validity and obviousness challenges because those components are disclosed in established products and regulatory materials.

When does articaine hydrochloride and epinephrine lose exclusivity?

The product’s principal U.S. market exclusivity is no longer the primary barrier to entry. Septocaine was approved in the United States in 2000, and the conventional five-year new chemical entity exclusivity period has long expired. Any pediatric exclusivity or regulatory exclusivity associated with the original approval also has expired.

The commercial protection profile is therefore driven by:

• FDA approval requirements for injectable dental anesthetics.
• Manufacturing and sterile-filling capability.
• Cartridge container-closure qualification.
• Product-specific labeling.
• Supplier quality and epinephrine stability.
• Dentist and distributor contracts.
• State and international registration requirements.

A new formulation could obtain three years of clinical-investigation exclusivity only if it met the statutory requirements for a new condition of use or change supported by new clinical investigations. A routine generic formulation would not normally receive new chemical entity exclusivity.

What is the Orange Book status of Septocaine and related products?

Septocaine is listed in FDA drug databases as an approved prescription dental injection containing articaine hydrochloride and epinephrine. The relevant reference products include:

Product	Active ingredients	Strength	Dosage form
Septocaine	Articaine HCl and epinephrine	40 mg/mL; 1:100,000	Dental injection
Septocaine	Articaine HCl and epinephrine	40 mg/mL; 1:200,000	Dental injection
Articadent and other products	Articaine HCl and epinephrine	Comparable strengths	Dental injection

The Orange Book should be reviewed at the time of filing to confirm current patent-listing status, therapeutic-equivalence codes and reference-product designations. The main regulatory risk is less likely to be an active composition patent and more likely to involve formulation sameness, cartridge performance, manufacturing controls and labeling.

Which companies are challenging or competing with articaine products?

Competition exists among branded dental anesthetic suppliers, generic manufacturers and regional distributors. Dentsply Sirona has been closely associated with Septocaine commercialization. Other market participants have marketed articaine products under regional or generic brands, including Septodont-associated products and manufacturers supplying Europe, Latin America, Asia-Pacific and the Middle East.

The competitive field includes:

• Branded articaine with epinephrine.
• Generic articaine with epinephrine.
• Articaine without epinephrine.
• Lidocaine with epinephrine.
• Mepivacaine, including plain and vasoconstrictor-containing products.
• Prilocaine with felypressin in selected markets.
• Bupivacaine for longer-duration dental anesthesia.

The most direct competitive comparison is between articaine and lidocaine. Articaine has strong dental-market recognition and favorable diffusion characteristics associated with its thiophene ring and ester group, while lidocaine has broader historical use, lower cost in many markets and extensive generic availability.

What commercial opportunities exist for new excipient strategies?

Sulfite-free articaine with epinephrine

A sulfite-free product would have the clearest excipient-based marketing proposition. The developer would need to protect epinephrine through packaging and process controls rather than conventional sulfite antioxidant protection.

Potential technologies include:

• Nitrogen purging during compounding and filling.
• Low-oxygen filling lines.
• High-barrier glass cartridges.
• Improved plunger and diaphragm materials.
• Light-resistant packaging.
• Oxygen scavengers in secondary packaging.
• Alternative antioxidant systems.

The main risks are epinephrine degradation, color formation, unknown degradation products, container compatibility and a higher cost of goods.

Preservative-free, single-use cartridge systems

Dental cartridges are already generally single-use and preservative-free in the conventional antimicrobial sense. Commercial differentiation can still arise through:

• Improved cartridge sterility assurance.
• Reduced breakage.
• Lower extractables and leachables.
• Better plunger glide force.
• Reduced residual volume.
• Compatibility with major dental aspirating syringes.
• Improved labeling and traceability.

A cartridge that reduces dead volume can generate measurable economic value for high-volume dental practices by reducing active-ingredient waste.

Lower-epinephrine presentations

The 1:200,000 presentation already addresses demand for lower vasoconstrictor exposure. Further opportunities may include:

• A broader strength portfolio.
• Clearer clinical positioning by procedure type.
• Unit-dose color coding.
• Packaging that reduces selection errors.
• Regional presentations aligned with local dental practice.

The product must avoid creating confusion between epinephrine ratios, which are expressed as 1 gram per volume and can be misread in clinical settings.

Improved patient comfort

Lower injection pain is a commercially relevant objective. Excipient and process variables include pH, buffer capacity, osmolality, injection force and cartridge temperature. A less acidic formulation may be attractive, but epinephrine stability can limit the available pH range.

A formulation claiming improved comfort would need clinical evidence. In vitro pH data alone would not establish a commercially meaningful patient benefit.

Sustainable packaging

Dental anesthetic cartridges generate recurring glass, elastomer and secondary-packaging waste. Opportunities include:

• Smaller cartons.
• Recyclable secondary packaging.
• Reduced plastic components.
• Lower-material cartridge systems.
• Supply-chain packaging optimized for temperature and breakage control.

Environmental claims must be supported by lifecycle and packaging data. The strongest near-term opportunity is likely packaging reduction rather than a complete replacement of the glass cartridge.

How strong is the patent estate for articaine hydrochloride and epinephrine?

The legacy patent estate is weak as a barrier to ordinary generic entry because the active ingredient and conventional combination have long commercial histories. A new patent estate could be moderate to strong only if it is built around a technically differentiated formulation or delivery system.

Patent category	Relative opportunity	Main vulnerability
Articaine composition of matter	Low	Legacy protection expired
Articaine and epinephrine combination	Low	Established commercial disclosure
Conventional sulfite formulation	Low	Likely obvious and known
Sulfite-free formulation	Moderate	Prior-art and enablement challenges
Oxygen-control process	Moderate	Narrow claim scope
Cartridge closure system	Moderate to high	Requires demonstrable performance
Improved comfort formulation	Moderate	Clinical proof required
Automated injector compatibility	Moderate	Device and combination-product issues
Manufacturing impurity-control process	Moderate	Trade-secret value may exceed patent value

Trade-secret protection may be more valuable than patents for compounding order, oxygen control, filling parameters, supplier specifications and in-process testing. Patent filings should be directed at measurable performance outcomes, such as reduced epinephrine degradation after accelerated storage or improved cartridge integrity.

What generic launch scenarios exist?

Standard ANDA-style launch

A conventional product would seek approval against the relevant reference product with matching active ingredients, strength, dosage form and route. The launch could compete on price, supply reliability and distributor access.

Paragraph IV challenge

A Paragraph IV filing would be relevant only if an unexpired Orange Book-listed patent were identified for the reference product. Given the mature history of articaine dental injections, the more likely route for a conventional entrant is a non-challenge filing or a product-specific regulatory pathway based on the applicable FDA requirements.

If a listed patent were present, the commercial analysis would include:

• Patent expiration and pediatric exclusivity.
• Certification timing.
• Potential 30-month stay.
• Paragraph IV notice.
• Declaratory or infringement litigation.
• Settlement terms.
• At-risk launch exposure.

505(b)(2) differentiated formulation

A sulfite-free formulation, modified cartridge system or materially different presentation could require a 505(b)(2) strategy rather than a conventional generic pathway, depending on the extent of formulation and labeling differences. This route could support differentiated labeling but may require additional stability, safety or clinical information.

Global-first launch

Markets outside the United States may provide earlier opportunities because registration pathways, patent-linkage rules and dental product classifications differ. Europe, Canada, Australia, Latin America and selected Asian markets have established demand for articaine products. The key issue is whether the product is regulated as a medicinal product, dental medicine or another national category.

What manufacturing and intellectual-property barriers affect commercialization?

The main manufacturing barrier is sterile cartridge production at scale. The product requires tight control of:

• Epinephrine oxidation.
• Dissolved oxygen.
• pH.
• Sterility.
• Endotoxins.
• Visible and subvisible particles.
• Cartridge fill volume.
• Container closure integrity.
• Glass delamination.
• Elastomer compatibility.
• Shipping temperature excursions.

Epinephrine is particularly sensitive to manufacturing variability. A supplier that can maintain stable color, assay and impurity profiles across multiple cartridge lots may have a practical advantage over a low-cost entrant.

Supply-chain concentration is another risk. Articaine hydrochloride, epinephrine, dental cartridges and specialized elastomer components may be sourced from a limited number of qualified suppliers. Dual sourcing can improve continuity but may trigger comparability work and regulatory variation filings.

What patent litigation and settlement risks apply?

No major current litigation conclusion should be assumed solely from the age of the product. The relevant review should cover:

• Current Orange Book listings for the reference NDA.
• Patent assignments and continuations.
• ANDA litigation records.
• Federal district court cases involving articaine products.
• FDA approval letters and labeling supplements.
• Settlement agreements affecting generic launch dates.
• Device or cartridge patents owned by packaging suppliers.

For a new formulation, litigation risk may shift from the active ingredient to the cartridge, filling process or combination-product design. Freedom-to-operate analysis should include dental injector compatibility, cartridge geometry, plunger materials and oxygen-barrier structures.

How does articaine compare with competing dental anesthetics?

Product	Primary commercial strength	Excipient or formulation opportunity
Articaine HCl with epinephrine	Strong dental positioning and multiple epinephrine ratios	Sulfite reduction, cartridge stability, comfort
Lidocaine with epinephrine	Broad availability and low cost	Premium delivery and low-volume systems
Mepivacaine plain	Useful where vasoconstrictor avoidance matters	Stability and preservative-free packaging
Bupivacaine	Longer duration	Improved tolerability and controlled-use packaging
Prilocaine-based products	Regional use and alternative vasoconstrictor systems	Market-specific formulation and safety positioning

Articaine’s commercial differentiation is strongest in dentistry, where cartridge format, injection handling and dentist familiarity matter as much as active-ingredient cost.

What revenue exposure and market-entry factors matter?

Revenue exposure is concentrated in dental procedures rather than hospital anesthesia. Demand is influenced by:

• Procedure volumes.
• Dental office utilization.
• Public and private reimbursement.
• Distributor contracts.
• Product shortages.
• Dentist preference.
• Cartridge availability.
• Regional adoption of articaine over lidocaine.

A new entrant should prioritize high-volume dental markets and distributor relationships. A differentiated product can command a premium only if it reduces clinical inconvenience, improves stability, lowers waste or addresses sulfite concerns.

The most defensible commercial model is a portfolio:

1. Standard 1:100,000 product for broad substitution.
2. 1:200,000 product for lower epinephrine exposure.
3. Sulfite-free or low-sulfite differentiated product.
4. Device-compatible cartridge presentation.
5. Region-specific packaging and regulatory configurations.

Key Takeaways

• Articaine hydrochloride and epinephrine is a mature combination with limited conventional patent barriers.
• The reference formulation uses articaine hydrochloride, epinephrine, sodium chloride, sodium metabisulfite and water for injection.
• Epinephrine oxidation is the central excipient and packaging problem.
• A sulfite-free formulation is the clearest differentiated opportunity but carries substantial stability and regulatory risk.
• Cartridge design, oxygen control, low residual volume and injector compatibility can create practical commercial advantages.
• Standard generic entry is likely to compete primarily on price, supply reliability and distributor coverage.
• A materially differentiated formulation may be better suited to a 505(b)(2) strategy than a conventional generic pathway.
• Patent value is likely to arise from specific formulation, packaging or manufacturing claims rather than from articaine itself.
• Biosimilar risk is not relevant because articaine hydrochloride and epinephrine is a small-molecule injectable, not a biologic.
• The strongest business case is a multi-strength, cartridge-based portfolio supported by formulation know-how and manufacturing control.

FAQs

Is sodium metabisulfite necessary in articaine with epinephrine?

It is commonly used to protect epinephrine from oxidative degradation. A product without sulfite would need an alternative stability strategy based on formulation, process and packaging controls.

Can articaine with epinephrine be marketed as a biosimilar?

No. The product is a small-molecule drug and would be regulated through a generic or other small-molecule pathway, not the biosimilar pathway.

What is the most valuable excipient innovation for articaine cartridges?

The highest-value opportunity is likely an oxygen-control and cartridge-closure system that preserves epinephrine stability while reducing or eliminating sulfite.

Does articaine require a preservative?

Conventional dental cartridges are single-use sterile products and generally do not require a multidose antimicrobial preservative. Antioxidant protection for epinephrine is a separate formulation issue.

What is the main regulatory risk for a new articaine formulation?

The main risk is failure to demonstrate long-term and accelerated stability for epinephrine, along with container-closure integrity, sterility, particulate control and compatibility with dental syringes.

References

1. U.S. Food and Drug Administration. (2023a). Septocaine (articaine hydrochloride and epinephrine) injection: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023b). ANDA submissions: Amendments and petition review. FDA.

4. U.S. Food and Drug Administration. (2023c). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. FDA.

5. U.S. Food and Drug Administration. (2023d). ICH Q1A(R2): Stability testing of new drug substances and products. FDA.

6. U.S. Food and Drug Administration. (2023e). ICH Q3C: Impurities: Guideline for residual solvents. FDA.

7. Septodont. (2023). Articaine hydrochloride and epinephrine dental injection product information. Septodont.